ISPECIMEN INC (ISPC)
US45032V1089 - Common Stock
We assign a fundamental rating of 3 out of 10 to ISPC. ISPC was compared to 40 industry peers in the Health Care Technology industry. While ISPC seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ISPC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ISPC has reported negative net income.
ISPC had a negative operating cash flow in the past year.
ISPC had negative earnings in each of the past 5 years.
In the past 5 years ISPC always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -70.12%, ISPC is not doing good in the industry: 69.23% of the companies in the same industry are doing better.
ISPC's Return On Equity of -113.88% is on the low side compared to the rest of the industry. ISPC is outperformed by 64.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.12% | ||
| ROE | -113.88% | ||
| ROIC | N/A |
ROA(3y)-45.63%
ROA(5y)-64.82%
ROE(3y)-64.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 51.41%, ISPC perfoms like the industry average, outperforming 46.15% of the companies in the same industry.
In the last couple of years the Gross Margin of ISPC has grown nicely.
ISPC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.41% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.92%
GM growth 5Y2.16%
2. Health
2.1 Basic Checks
ISPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ISPC has more shares outstanding than it did 1 year ago.
ISPC has more shares outstanding than it did 5 years ago.
ISPC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ISPC has an Altman-Z score of -6.41. This is a bad value and indicates that ISPC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.41, ISPC is doing worse than 87.18% of the companies in the same industry.
There is no outstanding debt for ISPC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.41 |
ROIC/WACCN/A
WACC10.39%
2.3 Liquidity
ISPC has a Current Ratio of 1.36. This is a normal value and indicates that ISPC is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.36, ISPC perfoms like the industry average, outperforming 43.59% of the companies in the same industry.
ISPC has a Quick Ratio of 1.36. This is a normal value and indicates that ISPC is financially healthy and should not expect problems in meeting its short term obligations.
ISPC has a Quick ratio (1.36) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.36 |
3. Growth
3.1 Past
ISPC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.31%.
ISPC shows a decrease in Revenue. In the last year, the revenue decreased by -4.47%.
Measured over the past years, ISPC shows a quite strong growth in Revenue. The Revenue has been growing by 17.73% on average per year.
EPS 1Y (TTM)-4.31%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-33.33%
Revenue 1Y (TTM)-4.47%
Revenue growth 3Y6.67%
Revenue growth 5Y17.73%
Revenue growth Q2Q-13%
3.2 Future
ISPC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.52% yearly.
Based on estimates for the next years, ISPC will show a quite strong growth in Revenue. The Revenue will grow by 10.54% on average per year.
EPS Next Y3.06%
EPS Next 2Y1.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11%
Revenue Next 2Y10.54%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ISPC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ISPC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.52%
EPS Next 3YN/A
5. Dividend
5.1 Amount
ISPC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ISPECIMEN INC
NASDAQ:ISPC (4/19/2024, 7:00:02 PM)
After market: 0.2978 +0.01 (+3.3%)0.2883
-0.13 (-31.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.62M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.12% | ||
| ROE | -113.88% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.41% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.36 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-4.31%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y3.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-4.47%
Revenue growth 3Y6.67%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y